111670-38-3

Upstream product

• 4224-70-8 6-bromohexanoic acid 
• 111670-37-2 6-Bromo-1,1,1-trifluorohexane 
• 603-35-0 triphenylphosphine 

Downstream Products

• 1292808-51-5 C₃₆H₄₇F₃O₃Si 
• 1292808-50-4 C₃₇H₄₉F₃O₃Si 
• 111670-42-9 [(3Z,5E,7E,11Z)-(2R,9R)-2,9-Bis-(tert-butyl-diphenyl-silanyloxy)-17,17,17-trifluoro-heptadeca-3,5,7,11-tetraenylsulfanyl]-acetic acid methyl ester 
• 111670-42-9 [(3Z,5E,7E,11Z)-(2R,9R)-2,9-Bis-(tert-butyl-diphenyl-silanyloxy)-17,17,17-trifluoro-heptadeca-3,5,7,11-tetraenylsulfanyl]-acetic acid methyl ester 
• 111670-40-7 (Z)-(2S,3R)-3-(tert-Butyl-diphenyl-silanyloxy)-11,11,11-trifluoro-undec-5-ene-1,2-diol 
• 111670-41-8 (Z)-(R)-2-(tert-Butyl-diphenyl-silanyloxy)-10,10,10-trifluoro-dec-4-enal 

Relevant academic research and scientific papers

DIHYDROPYRIDINONE MGAT2 INHIBITORS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Dihydropyridinone MGAT2 inhibitors

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

C20-trifluoro-5-oxo-ETE: A metabolically stable 5-oxo-ETE derivative

The total synthesis of C20-trifluoro-6(E),8(Z),11(Z),14(Z) 5-oxo-ETE is reported. This compound was designed as an ω-oxidation- resistant analog of 5-oxo-ETE that would be resistant to metabolism. The trifluoro derivative of 5-oxo-ETE stimulated calcium mobilization in neutrophils and desensitized these cells to subsequent exposure to 5-oxo-ETE.